Literature DB >> 15762370

Overdose of lomustine: report of two cases.

Abdullah Büyükçelik1, Hakan Akbulut, Bülent Yalçin, Feyyaz Ozdemir, Fikri Içli.   

Abstract

Two male patients with high-grade gliomas were treated with subtotal or total resection and radiotherapy followed by a lomustine-containing chemotherapy regimen. Both patients took lomustine at an oral dose of 800 mg over five days instead of their regular doses of 200 and 240 mg. Grade 4 neutropenia and thrombocytopenia developed in both patients within two weeks of the last lomustine dose. One of them was admitted to hospital because of febrile neutropenia. Neutropenia and thrombocytopenia were detected in the other patient when he was examined in the emergency room following a generalized convulsion. Both patients recovered from the severe myelosuppression caused by lomustine. No other organ toxicities were observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15762370     DOI: 10.1177/030089160409000618

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.

Authors:  Kader Yagiz; Tiffany T Huang; Fernando Lopez Espinoza; Daniel Mendoza; Carlos E Ibañez; Harry E Gruber; Douglas J Jolly; Joan M Robbins
Journal:  Neuro Oncol       Date:  2016-05-10       Impact factor: 12.300

2.  The management of lomustine overdose in malignant glioma patients.

Authors:  Hans-Georg Wirsching; Isabel Tritschler; Antonella Palla; Christoph Renner; Michael Weller; Ghazaleh Tabatabai
Journal:  Neurooncol Pract       Date:  2014-09-12

3.  Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.

Authors:  Funmilola A Fisusi; Adeline Siew; Kar Wai Chooi; Omotunde Okubanjo; Natalie Garrett; Katerina Lalatsa; Dolores Serrano; Ian Summers; Julian Moger; Paul Stapleton; Ronit Satchi-Fainaro; Andreas G Schätzlein; Ijeoma F Uchegbu
Journal:  Pharm Res       Date:  2016-02-22       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.